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The adjuvant therapy in gastric adenocarcinoma is supported by the U.S. Intergroup INT-0116. To apply the
same treatment and see if the results are comparable
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Materials/methods. Retrospective study in 119 p. with gastric adenocarcinoma underwent to surgery R0-1 and D2 lymphadenec-
tomy who received adjuvant QTRT like INT-0116 scheme. Statistical material SPSS 20.0. Average age 62. Males 67.2%. By location,
antrum 47.9%, body 36.1%, cardia 2.5% multicenter 4.2%, pylorus 6.7%, stump 2.5%. Total gastrectomy 43.7%. Edge+microscopic
13.4%. Media of lymph nodes removed: 19.23 (0–55). Affected lymph nodes. Average: 6.5 (0–33).
Results. Complete adjuvant therapy 87.9%. Toxicity with hospital admission 31.3%. Stadium: pT1 3.4%, pT2 33.1%, pT3 50.8%, pT4
12.7%, pN0 17.6%, pN1 40.3%, ≥pN2 42%. Toxicity ≥G2: hematologic 46.2%, gastrointestinal 19.3%, pain 1.7%, infection 10.1%,
none 20.2%. Median follow up 54 months. Overall survival at 3 years was 53.2%. SLE 42 months. Relapse: local 3.4%, peritoneal
11.8%, distant 24.4%. Signiﬁcant prognostic factors in multivariate analysis: stage, vasculolymphatic inﬁltration and lymph node
affectation.
Conclusions. The results obtained in our study, even with adverse prognostic factors, are comparable to those presented by the
U.S. Intergroup and conﬁrm the efﬁcacy of treatment with acceptable toxicity.
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Toxicity in rectal cancer patients treated with neoadjuvant radiotherapy combined with capecitabine vs.
raltitrexed
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Background and aim. Neoadjuvant treatment with concurrent radiochemotherapy improves local control in locally advanced
rectal cancer, however its toxicity proﬁle before and after surgery are still controversial. The aim of this retrospective study was
to evaluate the safety and tolerance of neoadjuvant chemoradiotherapy in rectal cancer patients treated either with capecitabine
or raltitrexed in combination with radiotherapy.
Methods. Retrospective data from 108 patients with locally advanced rectal cancer (T3-4 N0 M0/Tx N1–2 M0) treated preoperatively
with radiotherapy combined with oral capecitabine (825mg/m2 twice daily during radiotherapy) in 49 patients or intravenous
raltitrexed (3mg/m2 days 1-18-36) in 59 patients. The side effects of the treatment were evaluated in each group using The
Common Terminology Criteria for Adverse Events v.4.0.
Results. Toxicity grade 1–2 in patients treated with raltitrexed vs. capecitabine was as follows: vomiting 0 vs. 4.1%; diarrhea 30.5
vs. 42.9%; urinary 1.7 vs. 4.1%; radiodermatitis 37.3 vs. 26.6%; anemia 0% both; neutropenia 1.7 vs. 0%. Toxicity grade 3–4 in
patients treated with raltitrexed vs. capecitabine was as follows: vomiting 0% both; diarrhea 5.1 vs. 2,04%; urinary 3.4 vs. 0%;
radiodermatitis 6.8 vs. 2.04%; anemia 1.7 vs. 2,04%; neutropenia 1.7 vs. 0%.
Conclusions. Neoadjuvant radiotherapy associated with capecitabine or raltitrexed is well tolerated in rectal cancer patients, but
we can ﬁnd more events grade 3–4 in patients treated with raltitrexed. These data need to be conﬁrmed with prospective studies.
http://dx.doi.org/10.1016/j.rpor.2013.03.751
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Purpose. To analyze the feasibility, toxicity and efﬁcacy of triple drug docetaxel-based induction chemotherapy (ICHT) and
chemoradiotherapy (CHT-RT) in patients with locally advanced gastric or gastroesophageal cancer.
Methods. Patients with diagnostic of T3–T4 and/or N0-N+ gastric or gastroesophageal adenocarcinoma were planned to receive
three cycles of ICHT with capecitabine, oxaliplatin and docetaxel, followed by 45Gy of tridimensional conformal radiotherapy
and concurrent capecitabine, oxaliplatin and docetaxel. Surgery was scheduled 4–6 weeks after completion of CHT-RT. Toxicity
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was scored according to NCI-CTC, and pathologic response (PR) according to Becker tumor regression grade (TRG). Disease-free
survival (DFS) and overall survival (OS) were analyzed.
Results. A total of 73 patients were evaluated. Pretreatment T3–4 and/or N1 were encountered in 67 patients (92%). The median
cycles of ICHT were 3, and grade 3–4 (G3–4) hematological and gastrointestinal (GI) toxicity rate observed was 6% and 3%, respec-
tively. Seventy-two patients (98%) completed the planned RT dose. G3–4 hematological and GI toxicity was observed in 9 (12.4%)
and 3 patients (2.7%), respectively. Thirteen patients (17%) suffered G3–4 asthenia and/or hyporexia. Twenty-two (30%) patients
required admission in hospital. Sixteen patients developed metastasis during neoadjuvant treatment and 57 patients underwent
surgery (78%). The R0 resection rate was 95%. Twenty patients (35%) had TRG1a (complete tumor regression) PR, 13 patients (23%)
had TRG1b (<10% residual tumor), 15 patients (26%) had TRG2 (10–50% residual tumor) and 10 patients (16%) had TRG3 (>50%
residual tumor). Negative pathological lymph node (ypN0) was obtained in 35 patients (60.3%). After a median follow-up of 55
months, the 5-year OS and the 5-year DFS was 37% and 36%, respectively.
Conclusion. Triple drug docetaxel-based combination of ICHT and CHRT in locally advanced gastric and gastroesophageal adeno-
carcinoma is feasible and achieves signiﬁcant antitumor activity, with an acceptable toxicity proﬁle.
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